Healthcare / BiotechnologyNasdaqGM
$1.01
-0.07 (-6.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-114.6M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$66M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-105.4%
↓Gross Margin
N/A
•Debt/Equity
0.76
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+56.9%
FCF CAGR
—
FCF margin
-1353.3%
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.3M · net income $-129.8M · FCF $-139.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $10.3M | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M | $1.1M |
| Net Income | $-129.8M | $-129.8M | $-127.5M | $-89.2M | $-66.2M | $-48.6M | $-26.1M |
| EBITDA | $-124.1M | $-124.1M | $-119.7M | $-80.1M | $-59.9M | $-45.3M | $-25.0M |
| EPS | -1.00 | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 | — |
| Operating Margin | -1315.4% | -1315.4% | -4787.7% | -444.0% | -492.3% | -479.6% | -2417.8% |
| Net Margin | -1256.8% | -1256.8% | -4527.7% | -423.9% | -489.3% | -479.5% | -2408.0% |
| Balance Sheet | |||||||
| Debt/Equity | 0.76 | 0.76 | 0.40 | 0.61 | 0.86 | — | — |
| Current Ratio | 6.65 | 6.65 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-139.7M | $-139.7M | $-114.6M | $-64.5M | $-70.7M | $-58.6M | $-7.3M |
| Returns | |||||||
| ROE | -105.4% | -105.4% | -52.9% | -59.1% | -66.6% | -30.2% | 61.5% |
| Valuation | |||||||
| P/B | 1.06 | 1.06 | 1.42 | 2.54 | 0.46 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 266.7% | 266.7% | -86.6% | 55.5% | — | 834.7% | — |
| EPS Growth | 12.3% | 12.3% | 16.2% | 50.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.14 → -1.00
Residual
-29.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.